Approximately 30% of older adults exhibit the neuropathologic features of Alzheimer's disease (AD) without signs of cognitive impairment. Yet, little is known about the genetic factors that allow these potentially resilient individuals to remain cognitively normal in the face of substantial neuropathology. We performed a large, genome-wide association study (GWAS) of two previously validated metrics of cognitive resilience quantified using a latent variable modeling approach and representing betterthan-predicted cognitive performance for a given level of neuropathology. Data were harmonized across 5,108 participants from a clinical trial of AD and three longitudinal cohort studies of cognitive aging. All analyses were run across all participants and repeated restricting the sample to individuals with normal cognition to identify variants at the earliest stages of disease. As expected, all resilience metrics were genetically correlated with cognitive performance and education attainment traits (p-values<2.5x10 -20 ), and we observed novel correlations with neuropsychiatric conditions
Introduction
Alzheimer's disease (AD) is characterized by the presence of neuritic plaques and neurofibrillary tangles in the brain at autopsy. Clinically, it presents with progressive cognitive impairment. Yet, due to the long prodromal period of AD and unknown biological factors, not everyone with AD neuropathology presents with cognitive impairment. In fact, among cognitively normal volunteers agreeing to autopsy at the time of death, 70% have varying degrees of AD pathology (Sonnen et al., 2011) , and 30% have sufficient neuropathology in their brain to meet neuropathological criteria for AD (i.e., "Asymptomatic AD") (Rahimi and Kovacs, 2014) . Identifying the molecular factors that underlie the resilience observed in asymptomatic AD may provide novel therapeutic targets for clinical intervention and provide additional insight into the genetic architecture of AD.
While there has been some prior discovery work using genomic data Yu et al., 2018) , previous work characterizing the genetic contributors to asymptomatic AD has primarily focused on candidate genes (Monsell et al., 2013; Monsell et al., 2017; Franzmeier et al., 2019) due to the lack of sufficient sample size to complete full genome-wide analyses. A major barrier in moving analyses forward has been the categorical definitions of asymptomatic AD that drastically reduce the number of participants available for analysis. In the last decade, residual approaches to quantifying continuous metrics of "resilience" have emerged as potential endophenotypes for genetic analyses (Yu et al., 2015; White et al., 2017; Boyle et al., 2019) . The basic approach is to deconvolve cognitive scores into components that are explained and unexplained by proxy or direct measures of neuropathology (Reed et al., Genetic Markers of Resilience 6 2010) . These residual approaches model better-than and worse-than predicted cognitive performance to represent higher vs. lower resilience (Yu et al., 2015; Boyle et al., 2019) . Recently, our group has extended these residual approaches to quantify and validate continuous metrics of "cognitive resilience" (representing better-than-predicted cognitive performance given an individual's burden of AD neuropathology) and "brain resilience" (representing better-than-predicted brain volumes given an individual's burden of AD neuropathology) (Hohman et al., 2016b) . These continuous metrics are strong predictors of future cognitive decline and cognitive impairment (Hohman et al., 2016b) . The goal of the present analysis was to evaluate genetic predictors of cognitive resilience across the genome.
A few genome-wide analyses have been completed that focus on resilience in asymptomatic AD, although with limited sample sizes (Hohman et al., 2014a; Hohman et al., 2014b; Hohman et al., 2016a; White et al., 2017) . Recently, approximately 3,000 samples with both whole-genome genetic data and in vivo brain measures of amyloid burden from the Anti-Amyloid Treatment in Asymptomatic AD (A4) clinical trial were made publicly available, providing an unmatched resource for exploring the genetics of resilience to AD. We performed the largest (N=5,108) genome-wide association study (GWAS) of cognitive resilience in AD by leveraging harmonized resilience metrics across the cross-sectional A4 study and three longitudinal cohort studies of AD.
Validation of identified genomic candidates was completed using gene expression data from post mortem brain tissue and genotype data from large-scale case/control datasets of AD. Importantly, we also performed comprehensive genetic correlation and pathway analyses to provide critical information about the fundamental biological pathways that may protect the brain from the downstream consequences of AD neuropathology. Study. The A4 Study screening data were acquired as part of a clinical trial that began in 2014 (Sperling et al., 2014) . All participants were recruited with normal cognition, and amyloid Positron Emission Tomography (PET) imaging was performed at screening.
Materials and Methods

Participants
Additionally, participants with a Delayed Logical Memory score less than 6 or greater than 18 were excluded from PET scans and are not included in the present analysis.
ADNI was launched in 2003 and over the four phases of the study now includes >1,800 individuals age 55-90 (www.adni-info.org). Recruitment was designed to mimic clinical trials and therefore included individuals with normal cognition, mild cognitive impairment, and AD at baseline. Data from ADNI-1, ADNI-2, and ADNI-GO are included in the present analyses. ACT began in 1994 and recruited a random sample of nondemented older adults from the Seattle metropolitan area (Kukull et al., 2002) . A subset of participants in ACT agreed to brain donation and are included in these analyses. ROS launched in 1994 and recruited Catholic nuns, priests, and brothers from across the United States, and MAP launched in 1997 and recruited cognitively normal Genetic Markers of Resilience 8 older adults from the Chicago metropolitan area (Bennett et al., 2018) . Those who agreed to brain donation are included in the present analysis.
Amyloid PET Acquisition
For ADNI and A4 participants, amyloid burden was quantified using amyloid PET.
PET procedures in ADNI are described at the ADNI website (http://www.adni-info.org).
A4 and ADNI are both largescale multi-site studies for which PET amyloid acquisition was completed on multiple platforms, including GE, Philips, and Siemens. In all cases, PET data were acquired using a dynamic 3D scan with four 5-minute frames acquired 50-70 minutes post injection. A subset of ADNI participant data were acquired using 11 C-PiB, but the majority of ADNI and all of A4 was acquired using 18 F-Florbetapir.
Standardized uptake value ratios (SUVR) were quantified relative to whole cerebellum, and a composite mean SUVR was quantified across cortical regions as a summary metric of amyloid burden.
Amyloid PET Processing and Harmonization
Harmonization of amyloid PET levels was performed using composite cortical values calculated within ADNI and A4 separately. We applied a Gaussian Mixture Model (GMM) within each dataset to place values on the same scale using a recently developed harmonization algorithm (Properzi et al., 2019) . GMMs were estimated among cognitively normal individuals using a two-component model fit and applied to the entire sample. Mean SUVRs were scaled and normalized using the mean and standard deviation estimated from the predicted amyloid negative gaussian distribution.
A more comprehensive assessment of this and alternative harmonization approaches was recently published by our group (Raghavan et al., 2020) , but we used the present approach because it makes the fewest assumptions about the data and was more robust to outliers than alternative approaches. The final scaled score represents a zscore based on the predicted amyloid negative distribution among cognitively normal older adults.
Postmortem Assessment of Neuropathology
For ACT and ROS/MAP participants, neuritic plaque burden was quantified with CERAD scores. A comprehensive neuropathological evaluation was completed at each site, including full CERAD staging as previously described (Mirra et al., 1991) .
Neuropsychological Composites
Harmonization of cognitive tests in ADNI and A4 was completed using the Reminding Test or the delayed word recall from the ADAS-Cog. In all four datasets, a previously published protocol to harmonize neuropsychological scores in the domains of memory and executive function was used (Crane et al., 2017) . A memory composite was calculated in all four datasets, and an executive function composite was quantified in ACT, ADNI, and ROS/MAP (there was insufficient item level data in A4). A detailed description of the item level data and model that was included in these composite metrics is presented in Supplementary Methods.
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Quantification of Resilience Metrics
Resilience metrics were quantified using established procedures (Hohman et al., 2016b) and the model is presented in Fig. 1 . Briefly, individual regression models estimated amyloid pathology associations with cognition covarying for age and sex. A robust weighted least squares estimator in a confirmatory factor analysis was quantified using Mplus (Muthén and Muthén, 1998-2015) (version 7.31) to summarize residuals from the linear regression models into composite measures representing the degree to which an individual performed better or worse than predicted given their age, sex, and amyloid load (note that years of education was integrated into the second order latent 
Genotype Processing and Quality Control
Genotyping in all cohorts was performed using DNA extracted from whole blood or brain tissue on different genotyping arrays. For A4, the Illumina Global Screening Array was used for genotyping. ACT participants were genotyped on an Illumina Human660W-Quad. Three Illumina platforms were used in ADNI: Human610-Quad, HumanOmniExpress, and Omni 2.5M. ROSMAP genotypes were also obtained on three platforms: Affymetrix Genechip 6.0, Illumina Human1M, and Illumina Global Screening Array. In ADNI and ROSMAP, sample sets genotyped on different arrays were processed and imputed in parallel and merged after imputation. Quality control Genetic Markers of Resilience 11 (QC) was performed using standard procedures, including removal of SNPs and samples with >5% genotype missingness, removal of SNPs with <1% minor allele frequency (MAF) or Hardy-Weinberg Equilibrium (HWE) p-values <10 -6 , and removal of samples with sex discrepancies, cryptic relatedness (pi-hat >0.25), or who were not non-Hispanic White by self-report or by population principal component (PC) analysis.
Genotypes were then imputed with Minimac3 on the Michigan Imputation Server (https://imputationserver.sph.umich.edu) using the HRC r1.1 2016 reference panel.
Post-imputation QC steps included removal of SNPs with imputation quality score R 2 <0.90, call rate <95%, MAF <1%, or HWE p-value <10 -6 . Imputed datasets were then merged for the two autopsy cohorts (ACT and ROS/MAP) and the two PET imaging cohorts (A4 and ADNI). Non-overlapping SNPs (i.e., those with missingness >95%) were excluded. A total of 4,840,740 SNPs remained and were included in the analysis.
Statistical Analyses
Our analysis workflow is presented in Fig. 2 . Following phenotype harmonization and calculation of resilience metrics (i.e., Residual Cognitive Resilience and Combined Resilience) for each cohort, genome-wide association analyses were completed using linear regression in PLINK (version 1.9, https://www.cog-genomics.org/plink/1.9).
GWAS was performed in the combined autopsy dataset and the combined PET dataset.
For each dataset, two models were run. The first model estimated resilience among individuals across the spectrum of dementia, including individuals with normal cognition, mild cognitive impairment, and AD. The second model restricted the sample to individuals with normal cognition to focus on resilience during the preclinical phase of disease. In all models, covariates included age, sex, and the first three population PCs.
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The genome-wide threshold for statistical significance was set a priori at α=5x10 -8 .
Summary statistics at each marker across the autopsy dataset and the PET dataset were then combined in a fixed-effect meta-analysis using the GWAMA software program (Mägi and Morris, 2010) .
We first summarized genetic signal across the genome using summary statistics from our resilience GWAS to estimate genetic correlations between resilience phenotypes and 67 complex traits with publicly accessible GWAS summary statistics using the Genetic Covariance Analyzer (GNOVA) program (Lu et al., 2017) . Details about the source of summary statistics for each trait are presented in Supplementary   Table 1 . This provided a first level of validation that the genetic signal in our analysis was correlated with common phenotypes (e.g., cognitive performance and educational attainment) while also providing insight into novel resilience associations. Additionally, we replicated our top genomic correlation results leveraging the BADGERS program (Yan et al., 2018) and quantified correlation across 1,738 traits in the UK Biobank (http://biobank.ndph.ox.ac.uk/showcase/). To aid in interpretation of genetic covariance results, we also quantified heritability estimates using the Genome-wide Complex Trait Analysis (GCTA) tool (Yang et al., 2011) . Heritability of each resilience phenotype was quantified within the PET and Autopsy datasets separately, and within a combined dataset including all samples. Estimates were quantified across all participants and when restricting the sample to individuals with normal cognition.
Next, we performed gene-and pathway-level analyses using VEGAS2 (Liu et al., 2010; Mishra and Macgregor, 2015; Mishra and MacGregor, 2017) and PrediXcan (Gamazon et al., 2019) . PrediXcan models were estimated for 44 tissues in the GTEx Portal and for additional disease relevant tissues, including prefrontal cortex from CommonMind and monocytes from the Multi-Ethnic Study of Atherosclerosis (MESA).
Correction for multiple comparisons in gene-level analyses was quantified using the false discovery rate (FDR) procedure, which accounted for all 258,562 gene-tissue combinations. The a priori threshold for significance of the VEGAS pathway results was p<1x10 -5 , which was based on a simulation-derived 95% empirical significance threshold taking into account the multiple testing of 6,213 correlated pathways (Mishra and MacGregor, 2017) . 
Results
In total, 5,108 individuals across the four cohorts (A4 n=2,982; ROS/MAP n=1,031; ADNI n=688; ACT n=407) had both genome-wide genotype and resilience phenotype data, 3,820 (75%) of whom were cognitively normal. Participant characteristics are presented in Table 1 . In general, participants were mostly female (with the exception of ADNI) and were well-educated. Individuals in the PET cohorts tended to be younger than individuals in the autopsy cohorts.
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Genetic Covariance Results
Heritability estimates for each resilience phenotype are presented in Supplementary Table 2 Additionally, we observed multiple novel correlations, including two smoking behavior phenotypes: age at smoking initiation (genetic correlation=0.033; p=2.0x10 -7 ) and number of cigarettes per day (genetic correlation=-0.021; p=8.0x10 -4 ). Additional novel correlations included two neuropsychiatric conditions, whereby increased genetic risk of obsessive compulsive disorder (OCD) was correlated with higher levels of resilience (p=7.9x10 -4 ) while increased genetic risk of attention deficit hyperactivity disorder (ADHD) was associated with lower levels of resilience (p=4.7x10 -6 ).
Interestingly, older age at first birth was associated with higher levels of resilience (p=1.1x10 -8 ). Genetic correlations with Residual Cognitive Resilience were very similar to those observed for Combined Resilience and were similar when restricting the sample to cognitively normal individuals (Supplementary Tables 3-4) .
As a second level of validation, we also quantified genetic correlations with phenotypes in the UK Biobank leveraging a recently published method to perform phenome-wide association analyses leveraging summary statistics (Yan et al., 2018) .
Consistent with GNOVA results, we observed strong correlations with numerous education and cognitive phenotypes (Supplementary Tables 5-6 ). We also verified correlations with age at first birth (p=6.2x10 -12 ) and observed some intriguing novel correlations.
Interestingly, there was no evidence for genetic correlation between resilience phenotypes and clinical AD (p=0.45). Similarly, when evaluating the 40 previously identified AD risk variants from approximately 25 loci (Lambert et al., 2013; Jansen et al., 2019; Kunkle et al., 2019) , only three SNPs showed nominal evidence of association with either resilience phenotype ( Supplementary Table 7 ). Similar results were also observed when fully analyzing the APOE haplotype, whereby increasing numbers of APOE ε4 alleles or number of APOE ε2 alleles were not associated with either resilience phenotype (p-values>0.13). Together these results suggest the polygenic signal underlying the resilience phenotypes is distinct from clinical AD.
Gene-Level and Pathway Results
Next, we continued to explore the genetic architecture of resilience on both a gene and pathway level. Gene-level results in individual tissues and cross-tissue, based on predicted gene expression associations with resilience, are reported in Supplementary Tables 8-11 . Resilience metrics were not associated with predicted gene expression among individual tissues or across tissues after Bonferroni correction for multiple testing. The most significant gene in the cross-tissue analyses was ZNF451, which was associated with Combined Resilience in individuals with normal cognition at p<6.6x10 -6 (Supplementary Table 9 ).
In pathway-level analyses using VEGAS2, no molecular pathways remained significant when correcting for multiple comparisons. However, when restricting to cognitively normal participants in the Combined Resilience analysis, there was nominal evidence of enrichment in the dehydrogenase pathway (p=2.5x10 -5 ; PANTHER database) and the amino acid metabolism pathway (8.7x10 -5 ; PANTHER database).
Single-Variant Associations with Resilience
Finally, we focused on single variant level analyses to identify novel genetic loci associated with resilience. Genome-wide significant results are presented in Fig. 4a, and detailed results for all models are presented in Supplementary Tables 12-15 .
When including all diagnoses in the GWAS, we did not observe any variants that reached statistical significance in either Residual Cognitive Resilience or Combined Resilience analyses. When restricting analyses to individuals with normal cognition, we identified a locus on chromosome 18 just upstream of the ATP8B1 gene that reached genome-wide significance in Combined Resilience analyses (Fig. 4b) . More specifically, the minor allele of the index SNP at this locus (rs2571244; MAF=0.08) was associated with lower levels of Combined Resilience (β=-0.11, p=2.3x10 -8 ), and the direction of association was consistent across the PET and Autopsy datasets (Fig. 4c) . No genome-wide associations were observed in the Residual Cognitive Resilience analyses among participants with normal cognition.
Single-Variant Gene Mapping and Functional Annotation
To better characterize the molecular mechanisms of the genome-wide associated loci identified above, we utilized hundreds of functional genomics data sets to test for tissue-specific regulatory activity of these novel variants. The index SNP at the chromosome 18 locus (rs2571244) was strongly associated with prefrontal cortex methylation at multiple sites (Fig. 4a ) and the minor allele was associated with hypomethylation at a CpG site just upstream of ATPB81 (cg19596477; p=2x10 -13 ; Fig. 4b) . SNPs in this region also showed statistically significant enrichment for enhancer sites in the Roadmap dataset in across multiple tissues, including brain and liver (adjusted p-values=0.001). However, there was no evidence that rs2571244 functioned as an eQTL or hQTL in any of the databases.
Discussion
We completed a large genetic analysis of resilience to AD neuropathology and identified a number of variants, genes, and functional pathways that are associated with protection from the downstream consequences of neuropathology. Our results implicate genetic drivers of educational attainment, smoking behaviors, and neuropsychiatric phenotypes in AD resilience; highlight a novel resilience locus on chromosome 18; and implicate metabolism in the liver as a molecular contributor to resilience. Notably, the genetic architecture of resilience appears to be distinct from the genetic architecture of clinical AD, with no observed genetic correlation and nominal contributions of APOE on Genetic Markers of Resilience 18 resilience, suggesting that a focus on the molecular contributors to resilience may highlight novel pathways for therapeutic development.
Resilience Scores are Genetically Correlated with Education,
Neuropsychiatric, and Smoking Phenotypes
Results from genetic correlation analyses provided validation of the genetic signals we observed in this analysis and highlighted a number of important biological processes in the etiology of resilience. As expected, we observed strong genetic correlations with educational attainment, cognitive performance, and a number of education-related traits. It is also interesting that we observed some hormone and smoking related traits, although both may be confounded by educational attainment making interpretation challenging. In the case of the smoking traits, genetic risk for smoking and a younger age of initiating smoking was associated with lower levels of resilience, consistent with epidemiological associations between smoking and dementia (Tyas et al., 2003; Peters et al., 2008) . In the case of hormone-related phenotypes, an older age of first birth, last birth, and menopause (nominal association in GNOVA and UK Biobank) was correlated with higher resilience scores. Similar associations at the phenotypic level have been reported previously, with an older age at menopause correlated with protection from cognitive decline (Robert N. McLay et al., 2003; Ryan et al., 2009; Ryan et al., 2014) . Interestingly, we and others have published extensively on sex differences in the downstream consequences of neuropathology (Buckley et al., 2018; Deming et al., 2018; Hohman et al., 2018; Dumitrescu et al., 2019a; Dumitrescu et al., 2019b) . The present results suggest that hormone changes in older adulthood may contribute to susceptibility to cognitive decline, but more work is needed to disentangle the potential contribution of educational attainment on these observed genetic correlations.
In addition, we observed notable genetic correlations with neuropsychiatric phenotypes including ADHD and OCD. Interestingly, genetic risk for OCD was associated with higher resilience scores, while genetic risk for ADHD was associated with lower resilience. Although there is some literature suggesting a potential link between ADHD and dementia, it is challenging because of the symptomatic overlap of the two conditions in adulthood (Callahan et al., 2017) . Even less work has characterized the association between OCD and dementia, but the limited literatures suggests OCD is a risk factor for dementia (Dondu et al., 2015) . Thus, it is quite interesting that we observe a positive genetic correlation between OCD and resilience here, suggesting a potential protective role. Past work has highlighted a strong negative genetic correlation between OCD and metabolic phenotypes including body mass index, hip circumference, smoking, triglycerides, and insulin levels (Dondu et al., 2015) . OCD and ADHD also show a similar opposing genetic correlation with educational attainment, so it may be that the genetic correlation between these psychiatric conditions and resilience is secondary to metabolic or educational attainment phenotypes, but it is an area ripe for future investigation.
Variants near ATP8B1 are Associated with Resilience
Our top variant level association was observed on Chromosome 18 in relation to the Combined Resilience score that pools information from residual and proxy measures of reserve. The cluster of SNPs associated with Combined Resilience localized just upstream of ATP8B1, and the top SNP was robustly associated with Genetic Markers of Resilience 20 methylation at a site also just upstream of ATP8B1. Interestingly, prefrontal cortex methylation at this site was strongly associated with Combined Resilience scores in the ROS/MAP dataset, particularly among rs2571244 minor allele carriers, further implicating methylation as a potential biological driver at this locus. ATP8B1 is a protein coding gene that encodes an aminophospholipid translocase that is critical for maintaining bile acid homeostasis in the liver (Bull et al., 1998) . For that reason, we also performed post-hoc analyses using recently quantified metabolomic measures of 15 bile acids from serum samples in ADNI and observed that the variant was nominally associated with five bile acids, including TCA, GLCA, GCA, TDCA, and TCDCA (p<0.05; see Supplementary Table 16 ). Moreover, we observed significant associations between GLCA and TDCA on Combined Resilience, whereby higher levels of these bile acids were associated with lower levels of resilience ( Supplementary   Table 17 ). Bile acids have emerged as a potential biological contributor to AD, with recent work reporting differential abundance in AD cases compared to controls in both blood and brain , and other work reporting associations with biomarkers of AD neuropathology . Notably, both GLCA and TDCA were reported to have robust associations with hippocampal atrophy and glucose hypometabolism. The present findings therefore suggest genetic variation that predisposes some individuals towards a more detrimental bile acid state may also increase susceptibility to cognitive decline. The exact causal pathway of such bile acid effects is difficult to infer. Notably, the methylation QTL that we observed for rs2571244 was in prefrontal cortex, suggesting effects could be through brain, but there is a pressing need to better understand the gut-liver-brain axis and determine whether associations with cognitive aging and dementia are driven by metabolic processes in liver, gut, brain, or all three tissues.
Pathway Analyses Highlight Metabolism
While variant-level results implicate the metabolic processes in the liver, enrichment results highlight the related branched chain amino acid (BCAA) and dehydrogenase molecular pathways. Although the role of BCAAs in AD onset and progression is unclear, several studies have supported a connection. A previous GWAS study showed that SNPs associated with increased isoleucine plasma levels were also associated with AD (Larsson and Markus, 2017) . However, metabolomic studies have shown that increased serum concentration of BCAAs are associated with decreased AD risk (Tynkkynen et al., 2018) . Particularly, increased serum valine was associated with decreased rates of cerebral atrophy and cognitive decline (Toledo et al., 2017) . Deficits in brain BCAA metabolism have been proposed to contribute to the onset and progression of AD in mice, and increased circulating BCAAs have been hypothesized to increase neuronal mTOR signaling, leading to hyperphosphorylated tau pathology .
Several components of dehydrogenase pathways have been implicated to play a role in dysfunctional oxidative stress handling in AD (Martins et al., 1986) . Inhibition of alpha-ketoglutarate, pyruvate, and alcohol dehydrogenases by amyloid beta is thought to contribute to mitochondrial and metabolic dysfunction associated with AD (Casley et al., 2002; Yan and Stern, 2005) . Alpha-ketoglutarate dehydrogenase complex expression and activity is reduced in the temporal cortex of AD brains and is thought to reduce energy metabolism, contributing to neurodegeneration (Mastrogiacoma et al., 1996) .
Strengths and Limitations
This project has multiple strengths including the large, well characterized cohorts, the deep phenotypic data that allowed for a quantification of residual cognitive performance given level of amyloidosis, and the comprehensive follow-up analyses highlighting novel genes and pathways contributing to resilience. The study is not without limitations. Our sample was restricted to non-Hispanic white individuals who were healthy and highly educated, limiting generalizability beyond such populations. Additionally, while we were able to fully harmonize cognitive data within the autopsy and PET analyses separately, subtle differences in the scores across autopsy and PET remain possible due to limited availability of item anchors across all cohorts. Further, we were limited to cross-sectional analyses, which leave open the possibility that some individuals will later develop more severe pathology or cognitive impairment. Additional measures of neuropathology, particularly tau and cerebrovascular pathology, may have explained additional variance in cognitive performance and is an important area for future work. Moreover, the lack of extensive neuropsychological protocols in some datasets limited our ability to investigate other cognitive domains (e.g., language or visuospatial abilities). Finally, while this is the largest analysis of the genetic predictors of residual cognition completed to date, we remained underpowered to detect single variant effects, particularly at a low minor allele frequency. Continued efforts to pool, harmonize, and analyze biomarker, autopsy, and neuropsychological data from larger, Genetic Markers of Resilience 23 more representative cohorts will be needed to more fully characterize the genetic architecture of resilience.
Conclusions
We completed a large analysis of genetic resilience to AD and highlight several novel biological pathways that may protect the brain from the downstream consequences of amyloidosis. Our results implicate genetic drivers of bile acid homeostasis, vascular and metabolic risk factors, and neuropsychiatric conditions in AD resilience. 
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